You're contacting media contact of this press release

Title: Alfa Oncology Launches Brain Tumor-Related CRO Services Following Its TME Tech Platform

New York, United States, 30th Jan 2024, King NewsWire - Alfa Oncology, a leading biotechnology company specializing in oncology research and development, is pleased to announce the launch of its new Contract Research Organization (CRO) services specific to brain tumor research. This launch comes as a strategic move following the successful implementation of Alfa Oncology's innovative tumor microenvironment (TME) technology platform. Alfa Oncology’s cutting-edge TME technology platform consists of a series of separate business platforms, including microfluidics technology platform, sequencing technology platform, mass spectrometry technology platform, imaging technology platform, immune cell technology platform, stem cell technology platform, animal model technology platform, and animal experiment platform, etc. The TME center technology platform encompasses a wide range of capabilities such as single-cell omics of TME, animal model customization for TME, in vivo pharmacology targeting TME, and cell biology research. More importantly, this platform can freely combine technologies according to different research purposes to support various single or integrated projects. Building on this success, Alfa Oncology is now extending its expertise to focus on the challenging field of brain tumor research. Due to the complexity and resistance to traditional therapies, brain tumors present unique challenges. Responding to these challenges, Alfa Oncology provides neoantigen manufacturing and antibody drug development services for brain tumors through its proven technology platform. These include PD-1/PD-L1 antibodies for immune checkpoint inhibitors, antibodies that inhibit the CD161-CLEC2D pathway, and 124I-8H9 monoclonal antibodies targeting B7-H3. In addi...

This press release is issued by King Newswire